In summary, these findings provide a strong rationale for the development of small-molecule DHHC20 inhibitors, and the development of a combined regimen to treat Kras-mutant cancers with a DHHC20 inhibitor and a PI3K inhibitor. The gene discussed is ZDHHC20; the disease is cancer.